DiaMedica Therapeutics Inc. (NASDAQ: DMAC) reported Q3 EPS of ($0.17), in-line with the analyst estimate of ($0.17).

For earnings history and earnings-related data on DiaMedica Therapeutics Inc. (DMAC) click here.